We are analyzing https://link.springer.com/article/10.1007/s00277-013-1711-7.

Title:
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials | Annals of Hematology
Description:
Multiple myeloma (MM) is an incurable disease with a poor survival, which has not been affected even by high-dose chemotherapy. This systematic review was performed to assess the efficacy and safety of the novel agent bortezomib for patients with previously untreated MM. We systematically searched biomedical literature databases and identified randomized controlled trials (RCTs) comparing bortezomib with placebo, no bortezomib, or other active agents for patients with previously untreated MM. Overall survival (OS), reported as hazard ratio (HR) with 95 % confidence interval (CI), was the primary outcome measure. The secondary outcomes included time to progression (TTP), progression-free survival (PFS), and response rates. Five RCTs involving 2,728 patients were included. Three trials compared bortezomib with no bortezomib, and two compared bortezomib with other active agents (vincristine ± adriamycin-based chemotherapy). All included RCTs had methodological shortcomings, including no or unclear allocation concealment and blinding. Compared with no bortezomib or vincristine-based chemotherapy, the bortezomib-based regimen significantly improved the OS of patients with previously untreated MM. HR was 0.71 (95 % CI 0.55–0.93) and 0.77 (95 % CI 0.60–0.99), respectively. However, when compared with the vincristine + adriamycin-based regimen, the OS was similar (HR = 0.87, 95 % CI 0.57–1.33). TTP, PFS, and response rates were also improved in patients receiving bortezomib-based regimen. However, the risk of peripheral neuropathy was found to be significantly higher. In summary, bortezomib appears to improve survival and response rates of patients with previously untreated MM in spite of higher risk of peripheral neuropathy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,280,528 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, myeloma, bortezomib, multiple, google, scholar, pubmed, cas, patients, metaanalysis, previously, untreated, survival, therapy, dexamethasone, richardson, anderson, data, review, compared, treatment, phase, proteasome, inhibitor, clin, mitsiades, privacy, cookies, content, systematic, randomized, trials, access, cancer, induction, van, information, publish, search, march, chen, agents, study, mateos, san, miguel, res, hideshima, cell, transplantation,

Topics {✒️}

autologous stem-cell transplantation org/professionals/physician_gls/pdf/myeloma month download article/chapter junfang lin & junmin chen progression-free survival aggregate data meta-analysis proteasome inhibitor bortezomib high-dose chemotherapy randomized controlled trials induction pretransplantation therapy full article pdf multiple myeloma cells privacy choices/manage cookies incurable disease refractory multiple myeloma oncology—multiple myeloma san miguel jf natural science foundation vincristine-based chemotherapy perform meta-analyses de la rubia previously untreated mm european economic area primary outcome measure unclear allocation concealment clinical practice guidelines caspase-dependent downregulation overcomes drug resistance martin-ramos ml schmidt-wolf ig van der holt van der velde van marwijk-kooy article annals bortezomib-based consolidation individual patient data van de velde induction therapy article zeng conditions privacy policy consolidation therapy mateos mv fujian medical university junmin chen extracting summary statistics induction treatment prior richardson pg cancer res 61 cancer res 62 maintenance therapy

Questions {❓}

Stewart LA, Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
         description:Multiple myeloma (MM) is an incurable disease with a poor survival, which has not been affected even by high-dose chemotherapy. This systematic review was performed to assess the efficacy and safety of the novel agent bortezomib for patients with previously untreated MM. We systematically searched biomedical literature databases and identified randomized controlled trials (RCTs) comparing bortezomib with placebo, no bortezomib, or other active agents for patients with previously untreated MM. Overall survival (OS), reported as hazard ratio (HR) with 95 % confidence interval (CI), was the primary outcome measure. The secondary outcomes included time to progression (TTP), progression-free survival (PFS), and response rates. Five RCTs involving 2,728 patients were included. Three trials compared bortezomib with no bortezomib, and two compared bortezomib with other active agents (vincristine ± adriamycin-based chemotherapy). All included RCTs had methodological shortcomings, including no or unclear allocation concealment and blinding. Compared with no bortezomib or vincristine-based chemotherapy, the bortezomib-based regimen significantly improved the OS of patients with previously untreated MM. HR was 0.71 (95 % CI 0.55–0.93) and 0.77 (95 % CI 0.60–0.99), respectively. However, when compared with the vincristine + adriamycin-based regimen, the OS was similar (HR = 0.87, 95 % CI 0.57–1.33). TTP, PFS, and response rates were also improved in patients receiving bortezomib-based regimen. However, the risk of peripheral neuropathy was found to be significantly higher. In summary, bortezomib appears to improve survival and response rates of patients with previously untreated MM in spite of higher risk of peripheral neuropathy.
         datePublished:2013-03-02T00:00:00Z
         dateModified:2013-03-02T00:00:00Z
         pageStart:935
         pageEnd:943
         sameAs:https://doi.org/10.1007/s00277-013-1711-7
         keywords:
            Bortezomib
            Multiple myeloma
            Systematic review
            Meta-analysis
            Hematology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig4_HTML.gif
         isPartOf:
            name:Annals of Hematology
            issn:
               1432-0584
               0939-5555
            volumeNumber:92
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Zhiyong Zeng
               affiliation:
                     name:The First Affiliated Hospital of Fujian Medical University
                     address:
                        name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Junfang Lin
               affiliation:
                     name:The First Affiliated Hospital of Fujian Medical University
                     address:
                        name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Junmin Chen
               affiliation:
                     name:The First Affiliated Hospital of Fujian Medical University
                     address:
                        name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
      description:Multiple myeloma (MM) is an incurable disease with a poor survival, which has not been affected even by high-dose chemotherapy. This systematic review was performed to assess the efficacy and safety of the novel agent bortezomib for patients with previously untreated MM. We systematically searched biomedical literature databases and identified randomized controlled trials (RCTs) comparing bortezomib with placebo, no bortezomib, or other active agents for patients with previously untreated MM. Overall survival (OS), reported as hazard ratio (HR) with 95 % confidence interval (CI), was the primary outcome measure. The secondary outcomes included time to progression (TTP), progression-free survival (PFS), and response rates. Five RCTs involving 2,728 patients were included. Three trials compared bortezomib with no bortezomib, and two compared bortezomib with other active agents (vincristine ± adriamycin-based chemotherapy). All included RCTs had methodological shortcomings, including no or unclear allocation concealment and blinding. Compared with no bortezomib or vincristine-based chemotherapy, the bortezomib-based regimen significantly improved the OS of patients with previously untreated MM. HR was 0.71 (95 % CI 0.55–0.93) and 0.77 (95 % CI 0.60–0.99), respectively. However, when compared with the vincristine + adriamycin-based regimen, the OS was similar (HR = 0.87, 95 % CI 0.57–1.33). TTP, PFS, and response rates were also improved in patients receiving bortezomib-based regimen. However, the risk of peripheral neuropathy was found to be significantly higher. In summary, bortezomib appears to improve survival and response rates of patients with previously untreated MM in spite of higher risk of peripheral neuropathy.
      datePublished:2013-03-02T00:00:00Z
      dateModified:2013-03-02T00:00:00Z
      pageStart:935
      pageEnd:943
      sameAs:https://doi.org/10.1007/s00277-013-1711-7
      keywords:
         Bortezomib
         Multiple myeloma
         Systematic review
         Meta-analysis
         Hematology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-013-1711-7/MediaObjects/277_2013_1711_Fig4_HTML.gif
      isPartOf:
         name:Annals of Hematology
         issn:
            1432-0584
            0939-5555
         volumeNumber:92
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Zhiyong Zeng
            affiliation:
                  name:The First Affiliated Hospital of Fujian Medical University
                  address:
                     name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Junfang Lin
            affiliation:
                  name:The First Affiliated Hospital of Fujian Medical University
                  address:
                     name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Junmin Chen
            affiliation:
                  name:The First Affiliated Hospital of Fujian Medical University
                  address:
                     name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Hematology
      issn:
         1432-0584
         0939-5555
      volumeNumber:92
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The First Affiliated Hospital of Fujian Medical University
      address:
         name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
         type:PostalAddress
      name:The First Affiliated Hospital of Fujian Medical University
      address:
         name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
         type:PostalAddress
      name:The First Affiliated Hospital of Fujian Medical University
      address:
         name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Zhiyong Zeng
      affiliation:
            name:The First Affiliated Hospital of Fujian Medical University
            address:
               name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
               type:PostalAddress
            type:Organization
      name:Junfang Lin
      affiliation:
            name:The First Affiliated Hospital of Fujian Medical University
            address:
               name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
               type:PostalAddress
            type:Organization
      name:Junmin Chen
      affiliation:
            name:The First Affiliated Hospital of Fujian Medical University
            address:
               name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
      name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
      name:Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(88)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.7s.

LINK . SPRINGER . COM {}